new alzheimer's drug, ntrx-07, was safe in a phase 2a trial. that's early, but it's progress. it highlights how seriously we're finally taking brain inflammation as a target for treating this disease.
Been using this to practice my English:
https://app.speakfloe.com/#/onboarding/goals
Been using this to practice my English:
https://app.speakfloe.com/#/onboarding/goals
April 7, 2026 at 8:05 PM
new alzheimer's drug, ntrx-07, was safe in a phase 2a trial. that's early, but it's progress. it highlights how seriously we're finally taking brain inflammation as a target for treating this disease.
Been using this to practice my English:
https://app.speakfloe.com/#/onboarding/goals
Been using this to practice my English:
https://app.speakfloe.com/#/onboarding/goals
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026#London#UK#Alzheimer's_Disease#NeuroTherapia#NTRX-07
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026
At the AAIC 2026 Conference in London, NeuroTherapia will unveil data from its Phase 2a clinical trial of NTRX-07 for Alzheimer's disease, highlighting significant safety and biomarker results.
third-news.com
July 13, 2026 at 10:14 AM
NeuroTherapia to Reveal Promising Findings in Alzheimer's Trial at AAIC 2026#London#UK#Alzheimer's_Disease#NeuroTherapia#NTRX-07
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, April 8, 2026
By: Salong Debbarma on Wednesday, April 8, 2026
NeuroTherapia concludes Phase IIa trial of NTRX-07 for Alzheimer’s
NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease treatment.
www.clinicaltrialsarena.com
April 9, 2026 at 10:44 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, April 8, 2026
By: Salong Debbarma on Wednesday, April 8, 2026
NeuroTherapia's Phase 2a Trial Results for Alzheimer's Treatment Promising for Future Developments#USA#Cleveland#Alzheimer's#NeuroTherapia#NTRX-07
NeuroTherapia's Phase 2a Trial Results for Alzheimer's Treatment Promising for Future Developments
NeuroTherapia has successfully finished its Phase 2a trial for a new Alzheimer's drug, showcasing safety and encouraging early results that pave the way for future studies.
third-news.com
April 7, 2026 at 1:19 PM
NeuroTherapia's Phase 2a Trial Results for Alzheimer's Treatment Promising for Future Developments#USA#Cleveland#Alzheimer's#NeuroTherapia#NTRX-07
NeuroTherapia Secures EMA Approval for Phase 2 Alzheimer's Treatment Trial#United_States#Cleveland#Alzheimer's#NeuroTherapia#NTRX-07
NeuroTherapia Secures EMA Approval for Phase 2 Alzheimer's Treatment Trial
NeuroTherapia has received EMA approval for its Phase 2 trial of NTRX-07 for Alzheimer's, focusing on safety, pharmacokinetics, and efficacy.
third-news.com
February 4, 2025 at 2:40 PM
NeuroTherapia Secures EMA Approval for Phase 2 Alzheimer's Treatment Trial#United_States#Cleveland#Alzheimer's#NeuroTherapia#NTRX-07